[HTML][HTML] Prolonged higher dose methylprednisolone versus conventional dexamethasone in COVID-19 pneumonia: a randomised controlled trial (MEDEAS)

…, AT Gaccione, M Romagnoli, A Fraccaro… - European …, 2023 - Eur Respiratory Soc
Background Dysregulated systemic inflammation is the primary driver of mortality in severe
coronavirus disease 2019 (COVID-19) pneumonia. Current guidelines favour a 7–10-day …

[HTML][HTML] Pneumothorax and/or pneumomediastinum worsens the prognosis of COVID-19 patients with severe acute respiratory failure: a multicenter retrospective case …

M Bonato, A Fraccaro, N Landini, G Zanardi… - Journal of Clinical …, 2021 - mdpi.com
Pneumothorax (PNX) and pneumomediastinum (PNM) are potential complications of COVID-19,
but their influence on patients’ outcomes remains unclear. The aim of the study was to …

[HTML][HTML] Multidimensional 3-month follow-up of severe COVID-19: airways beyond the parenchyma in symptomatic patients

M Bonato, P Peditto, N Landini, A Fraccaro… - Journal of Clinical …, 2022 - mdpi.com
SARS-CoV-2 may lead to a large spectrum of respiratory manifestations, including pulmonary
sequelae. We conducted a single-center longitudinal study of survivors from severe COVID…

Evasione fiscale e Tax Morale

A Fraccaro - 2016 - dspace.unive.it
Evasione fiscale e Tax Morale Evasione fiscale e Tax Morale DSpace/Manakin Repository
Login DSpace Home → Università Ca' Foscari Venezia → Archivio delle tesi → Tesi di laurea …

Tissue expression of Th2 markers: comparison between idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis

A Fraccaro, A Montero-Fernandez… - C75. FIBROSIS …, 2017 - atsjournals.org
Results:(95% CI) percent of tissue occupied by IL13 was 10.2%(5.2-19.1) in fibrotic HP versus
5.57%(4.1-7.3) in IPF (p= 0.007), for IL25 it was 5.1%(2.8-6.8) in fibrotic HP (p= 0.02) vs 3…

Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF)

…, G Turato, D Biondini, S Pavanello, A Fraccaro… - 2016 - Eur Respiratory Soc
The clinical course of IPF is heterogeneous and unpredictable, however a rapid decline in
FVC and telomere shortening appear to be related to worse prognosis. It has been shown that …

[PDF][PDF] Pulmonary fibrosis: key features and challenges

A Fraccaro, E Renzoni - Minerva, 2016 - researchgate.net
… (Cite this article as: Fraccaro A, Renzoni E. Pulmonary fibrosis: key features … Alessia Fraccaro
and Elisabetta Renzoni contributed equally to this manuscript. Funding.—Alessia Fraccaro

HRCT in the evaluation of functional decay in IPF

…, G Turato, R Polverosi, D Biondini, A Fraccaro… - 2016 - Eur Respiratory Soc
Background: The clinical course of IPF is heterogeneous however it is recognized that patients
can have a slow (S) or rapid (R) progression of the disease and that R is related to worse …

Innate immunity cell activation in virologically suppressed HIV-infected maraviroc-treated patients

…, A Di Biagio, A Parodi, F Bozzano, P Fraccaro… - AIDS, 2014 - journals.lww.com
This is a cross-sectional, case–control study analyzing the effect of antiretroviral therapy (ART)
including or not maraviroc, on circulating monocytes and natural killer cells. Sixty-eight …

Informatics for Health 2017: Advancing both science and practice

…, N Peek, P Fraccaro… - Journal of …, 2017 - research-repository.st-andrews.ac …
Introduction : The Informatics for Health congress, 24-26 April 2017, in Manchester, UK,
brought together the Medical Informatics Europe (MIE) conference and the Farr Institute …